| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss for the period | -34,395 | -26,419 |
| Depreciation of property and equipment (note 5) | 311 | 218 |
| Amortization of intangible assets (note 6) | 140 | 86 |
| Non-cash lease expense adjustment | 28 | 19 |
| Share-based compensation (note 10) | 4,109 | 2,440 |
| Interest and accretion expense | 58 | 51 |
| Trade and other receivables (note 3) | 908 | -2,449 |
| Inventory (note 4) | 2,593 | 2,723 |
| Prepaid expenses and deposits | -1,158 | -1,042 |
| Accounts payable, accrued expenses and other liabilities (note 7) | 338 | 545 |
| Deferred revenue | 101 | 317 |
| Income taxes payable | 58 | - |
| Deferred tax liabilities | 10 | -14 |
| Net cash used in operating activities | -31,641 | -22,027 |
| Repayments of long-term debt (note 8) | 290 | 290 |
| Net cash provided by (used in) financing activities | -290 | -290 |
| Net increase (decrease) in cash | -31,931 | -22,317 |
| Effect of exchange rate changes on cash | 1,845 | - |
| Cash and cash equivalents at beginning of period | 54,912 | - |
| Cash and cash equivalents at end of period | 24,826 | - |
Profound Medical Corp. (PROF)
Profound Medical Corp. (PROF)